Last reviewed · How we verify
NCT07128498
Tinkering to Flex Ur Brain (Tinker-FUN): A Cognitive Flexibility Pilot Program for Community Dwelling Older Adults
NA trial testing Tinker-Fun in Cognition Improvement in 15 participants. Not yet recruiting.
31 August 2026
Quick facts
| Lead sponsor | University of Florida |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 15 |
| Start date | 15 January 2026 |
| Primary completion | 31 August 2026 |
| Estimated completion | 31 August 2026 |
Drugs / interventions tested
- Tinker-Fun
Conditions studied
- Cognition Improvement — all drugs for Cognition Improvement →
Sponsor
University of Florida
Who can join
Adults 65 to 85, any sex, with Cognition Improvement. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Tinker-FUN program is a cognitive flexibility intervention designed to help older adults adapt to aging and live independently. While cognitive training is an effective way to mitigate cognitive decline, current methods do not focus on cognitive flexibility, an essential aspect of managing daily activities as one ages. The intervention aims to address this gap by offering engaging tinkering activities designed for older adults. Before expanding to a larger clinical trial, the current proposal seeks to test its feasibility among community-dwelling older adults in US.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07128498
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Florida trials
Trials by the same sponsor.
- NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
- NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
- NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
- NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
- NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07128498 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Florida
- Last refreshed: 19 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07128498.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing